Immunoadjuvant Nanoparticles as Trojan Horses for Enhanced Photo-Immunotherapy in the Treatment of Triple-Negative Breast Cancer

被引:8
|
作者
Wu, Jinxian [1 ,2 ]
Wang, Shanyong [1 ,2 ]
Liu, Shanshan [1 ,2 ]
Liu, Fang [1 ,2 ]
Zhou, Feifan [1 ,2 ]
机构
[1] Hainan Univ, Sch Biomed Engn, Key Lab Biomed Engn Hainan Prov, Haikou, Peoples R China
[2] Hainan Univ, One Hlth Inst, Haikou, Peoples R China
基金
中国国家自然科学基金;
关键词
triple-negative breast cancer; nanoparticles; phototherapy; immunotherapy; metastasis; immune response;
D O I
10.3389/fphar.2022.883428
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment of triple-negative breast cancer (TNBC) faces great challenges due to high invasiveness and poor prognosis. Therefore, effective treatment methods are urgently needed to control primary tumors and suppress distant tumors. Herein, we employed glycated chitosan (GC), a polysaccharide macromolecular immunoadjuvant, to construct a self-assembly GC@ICG nanoparticle which is accessible to tumor cells for synergistic cancer treatment based on the combination of phototherapy and immunotherapy. In this strategy, the self-associated synthesis of spherical GC@ICG significantly improved the stability of ICG and endowed GC with Trojan Horses in tumor cells to enhance tumor immunogenicity. A bilateral 4T1 tumor-bearing mouse model was established to evaluate the therapeutic outcomes and specific host antitumor immune response. Finally, GC@ICG-based phototherapy can directly eliminate primary tumors and resist the progression of untreated distant tumors. In addition, compared to the treatment of L + GC + ICG, GC@ICG-based phototherapy was evidenced to suppress lung metastasis and enhance infiltration of CD8(+) T cells in untreated distant tumors. Therefore, this design shows promise in addressing the challenges of the treatment of TNBC.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
    Wesolowski, Jakub
    Tankiewicz-Kwedlo, Anna
    Pawlak, Dariusz
    CANCERS, 2022, 14 (16)
  • [2] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [3] Immunotherapy in triple-negative breast cancer
    Katz, Heather
    Alsharedi, Mohamed
    MEDICAL ONCOLOGY, 2018, 35 (01)
  • [4] Immunotherapy for Triple-Negative Breast Cancer
    Cao, Yifeng
    Chen, Chuyang
    Tao, Yi
    Lin, Weifeng
    Wang, Ping
    PHARMACEUTICS, 2021, 13 (12)
  • [5] Immunotherapy in triple-negative breast cancer
    Heather Katz
    Mohamed Alsharedi
    Medical Oncology, 2018, 35
  • [6] Oncolytic Immunotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer
    Bramante, Simona
    Koski, Anniina
    Liikanen, Ilkka
    Oksanen, Minna
    Joensuu, Timo
    Pesonen, Sari
    Hemminki, Akseli
    MOLECULAR THERAPY, 2015, 23 : S173 - S173
  • [7] Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer
    McArthur, Heather
    ONCOLOGY-NEW YORK, 2019, 33 (04): : 137 - 140
  • [8] The Use of Immunotherapy in Triple-Negative Breast Cancer
    Schmid, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 770 - 773
  • [9] Advances in immunotherapy for triple-negative breast cancer
    Yang Liu
    Yueting Hu
    Jinqi Xue
    Jingying Li
    Jiang Yi
    Jiawen Bu
    Zhenyong Zhang
    Peng Qiu
    Xi Gu
    Molecular Cancer, 22
  • [10] Role of Immunotherapy in Triple-Negative Breast Cancer
    Keenan, Tanya E.
    Tolaney, Sara M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 479 - 489